Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
8,942
datasets available to search
ShareScore release 0.9.0
Dataset results
8,942 results for “Prostate”
Multi-cohort effectiveness of Gallium-68-PSMA PET/CT and pelvic 3Tesla multi-parametric magnetic resonance imaging in the diagnostic and therapeutic work-up of prostate cancer (MoH RF-2016-02364230)
<p>The project "<strong>Multi-cohort effectiveness of Gallium-68-PSMA PET/CT and pelvic 3Tesla multi-parametric magnetic resonance imaging in the diagnostic and therapeutic work-up of prostate cancer</strong>" is funded by Italian Ministry of Health (project code: <strong>RF-2016-02364230</strong>)</p><p> </p><p>Based on preliminary data, the project hypothesis was that diagnostic accuracy of 68Ga-PSMA PET/CT is comparable to that of mp-3TMRI in pts with pCa. If that is the case, the use of 68Ga-PSMA PET/CT will lead to shorter waiting lists, faster scanning time and lower costs compared to mp-3TMRI. The 1st goal of this project is to guide or replace invasive procedures with a non invasive approach such as mp-3TMRI or 68Ga-PSMA PET/CT. The secondary aim is a comparative analysis of the 2 techniques. </p><p><strong>Specific Aim 1:</strong></p><p>Characterize the incremental benefit of pelvic mp-MRI and 68Ga-PSMA PET/CT in: guiding TRUS-B, to identify clinicallysignificant PCa in pts who are negative at first-round TRUS-B and/or are undergoing AS.</p><p>Stage accuracy of pelvic mp-MRI and 68Ga PSMA PET/CT during the pre-surgical work-up of high-risk PCa pts and PCa pts who are candidates for nerve-sparing surgery.</p><p>The secondary aim is a comparative analysis of the 2 techniques.</p><p><strong>Specific Aim 2:</strong></p><p>Evaluate the accurancy of 68Ga-PSMA PET/CT (i.e. Sensitivity, SE; specificity, SP) in detecting sites of biochemical PCa recurrence compared to routinely-used diagnostic tools (TRUS-B, bone scan, diagnostic CT, MRI and 18F-FCH PET/CT).</p><p>The secondary objectives are SE for different PSA values and SE for different Gleason score.</p><p><strong>Specific Aim 3:</strong></p><p>Evaluate the efficacy in terms of Disease Control Rate (DCR) and the safety of 2 different administration schedules of 177Lu-PSMA in a cohort (C) of metastatic CRPC pts previously treated with standard therapy.</p>
BIMCV-Prostate-Dataset V1
<p>The <strong>BIMCV Prostate Dataset</strong> is a comprehensive and diverse dataset that includes a total of 9,341 prostate MRI sessions, distributed among 8,441 subjects, collected from 16 healthcare centers in the Valencian Community, Spain. This dataset is structured according to the <strong>MIDS (Medical Imaging Data Structure) </strong>standard, ensuring consistent and accessible organization for researchers, facilitating data use and analysis.</p> <p>The first version of the dataset focuses on sessions that contain the three mentioned imaging modalities (T2W, DWI, and ADC), resulting in a total of <strong>1,730 complete sessions, with a total of 4,663 samples for training, of which 2,594 are csPCa positive and 2,069 are csPCa negative</strong>. This information can be found in the table available on GitHub.</p> <p>The dataset includes MRI images in three modalities: T2-weighted images (T2W), diffusion-weighted images (DWI), and apparent diffusion coefficient (ADC) maps. In total, the dataset includes 32,662 T2W images (62.97%), 8,036 DWI images (15.49%), and 11,167 ADC maps (21.53%), including both the original maps and those calculated from the available DWI images. This additional calculation process was carried out to ensure the dataset's integrity and consistency, allowing for comprehensive analysis in the field of prostate oncology.</p> <p>The exploratory data analysis (EDA) performed on this dataset has provided insights into the characteristics and distribution of the images, ensuring the dataset's representativeness and diversity. For example, it was found that Health Center 5 contributed the highest proportion of sessions (15.6%), followed by Health Center 7 (12.3%) and Health Center 17 (10.5%). This level of diversity in data sources ensures that the dataset encompasses a wide range of imaging acquisition practices and patient demographics, improving the generalization of artificial intelligence models developed with this data.</p> <p>Additionally, the analysis of the distribution by MRI equipment manufacturer revealed that most images were acquired with General Electric equipment (66.7%), followed by Philips (25.1%) and Siemens (8.13%). Similarly, most sessions were conducted with 1.5 Tesla machines (63%), followed by 3.0 Tesla machines (36.5%), reflecting standard clinical practices in the region.</p> <p>Regarding the distribution of labels within the dataset, of the total cases, 4,871 (approximately 52%) are labeled as csPCa positive, while 3,514 cases (approximately 37%) are labeled as csPCa negative.</p> <p><strong>To access the dataset, please fill out the following survey: <a href="https://forms.office.com/e/frV3A5dT6r" target="_new" rel="noopener">https://forms.office.com/e/frV3A5dT6r</a></strong></p> <p><br><br>El <strong>BIMCV Prostate Dataset</strong> es un conjunto de datos integral y diverso que incluye un total de 9,341 sesiones de resonancia magnética de próstata, distribuidas entre 8,441 sujetos, recopiladas en 16 centros de salud de la Comunidad Valenciana, España. Este conjunto de datos está estructurado según el estándar <strong>MIDS (Medical Imaging Data Structure)</strong>, lo que garantiza una organización coherente y accesible para los investigadores, facilitando la utilización y análisis de los datos.</p> <p>La primera versión del dataset se centra en las sesiones que contienen las tres modalidades de imagen mencionadas (T2W, DWI y ADC), lo que ha dado lugar a un total de <strong>1,730 sesiones completas, con un total de 4663 muestras para entrenamiento, de los cuales 2,594 son csPCa positivo y 2,069 csPCa negativo</strong>. Esta información puede ser encontrada en la tabla presente en GitHub.</p> <p>El conjunto de datos incluye imágenes de resonancia magnética en tres modalidades: imágenes ponderadas en T2 (T2W), imágenes de difusión ponderada (DWI) y mapas de coeficiente de difusión aparente (ADC). En total, el dataset incluye 32,662 imágenes T2W (62.97%), 8,036 imágenes DWI (15.49%), y 11,167 mapas ADC (21.53%), que incluyen tanto los mapas originales como los calculados a partir de las imágenes DWI disponibles. Este proceso de cálculo adicional se realizó para asegurar la integridad y consistencia del conjunto de datos, permitiendo un análisis exhaustivo en el ámbito de la oncología de próstata.</p> <p>El análisis exploratorio de datos (EDA) realizado sobre este conjunto de datos ha permitido entender las características y la distribución de las imágenes, lo que garantiza la representatividad y diversidad del dataset. Por ejemplo, se ha encontrado que el Centro de Salud 5 contribuyó con la mayor proporción de sesiones (15.6%), seguido del Centro de Salud 7 (12.3%) y el Centro de Salud 17 (10.5%). Este nivel de diversidad en las fuentes de datos asegura que el dataset abarca una amplia gama de prácticas de adquisición de imágenes y demografías de pacientes, mejorando la generalización de los modelos de inteligencia artificial desarrollados con estos datos.</p> <p>Además, el análisis de la distribución por el fabricante del equipo de resonancia magnética reveló que la mayoría de las imágenes fueron adquiridas con equipos de General Electric (66.7%), seguidos por Philips (25.1%) y Siemens (8.13%). Asimismo, la mayoría de las sesiones se realizaron con máquinas de 1.5 Tesla (63%), seguidas de máquinas de 3.0 Tesla (36.5%), reflejando las prácticas clínicas estándar en la región.</p> <p>En cuanto a la distribución de las etiquetas dentro del dataset, de los casos totales, 4871 (aproximadamente el 52%) están etiquetados como csPCa positivo, mientras que 3514 casos (aproximadamente el 37%) están etiquetados como csPCa negativo.<br><br><strong>Para acceder al dataset por favor rellene la siguiente encuesta: https://forms.office.com/e/frV3A5dT6r</strong></p>
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
ClinicalTrials.gov study NCT04377152. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Stockholm3 Use Prior to MRI for Prostate Cancer Detection in a Clinical Care Pathway: a Multi-centered Validation
ClinicalTrials.gov study NCT06573736. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
ClinicalTrials.gov study NCT00244920. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer
ClinicalTrials.gov study NCT02998242. IPD Sharing: YES. Countries: 0. Publications: 0.
Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
ClinicalTrials.gov study NCT03147196. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Selenium in Preventing Prostate Cancer
ClinicalTrials.gov study NCT00978718. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
ClinicalTrials.gov study NCT06527690. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)
ClinicalTrials.gov study NCT00140387. IPD Sharing: Not stated. Countries: 0. Publications: 0.
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
ClinicalTrials.gov study NCT02588404. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
ClinicalTrials.gov study NCT04489745. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
ClinicalTrials.gov study NCT00416533. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Memantine Hydrochloride in Prostate Cancer Patients
ClinicalTrials.gov study NCT07164794. IPD Sharing: YES. Countries: 0. Publications: 0.
Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)
ClinicalTrials.gov study NCT02244346. IPD Sharing: Not stated. Countries: 0. Publications: 0.
MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy
ClinicalTrials.gov study NCT00963300. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ClinicalTrials.gov study NCT06765954. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer
ClinicalTrials.gov study NCT05574712. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Osteosclerotic Changes on CT Predict Survival in Prostate Cancer
ClinicalTrials.gov study NCT06883474. IPD Sharing: NO. Countries: 0. Publications: 0.
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
ClinicalTrials.gov study NCT01048151. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.